The medication's dual agonism of GIP and GLP-1 receptors triggers physiological changes that may collectively influence cardiovascular parameters, though many proposed mechanisms are based on GLP-1 receptor agonist class effects and require further confirmation specific to tirzepatide
See also: GLP-1 Guides | Peptide Guides Written by Rachel Kim, MS, RD , Registered Dietitian & Health Writer Medically reviewed by FormBlends Clinical Review , Clinical Pharmacist & Medical Reviewer Published: Key Takeaway Complete comparison of 5 leading GH peptides: Ipamorelin, CJC-1295, Sermorelin, GHRP-2, and MK-677
Designed to Minimize Discomfort: Microdosing aims to deliver the benefits of Tirzepatide while helping to reduce the likelihood of common side effects such as nausea or gastrointestinal discomfort
Each panelist brought a unique perspective to the table, discussing how they work with and reach GLP-1 medication users as well as key considerations and implications for practice and the broader healthcare, food and beverage community
Treatment goals focus on glycemic control, weight management, and comprehensive cardiometabolic risk reduction rather than targeting inflammatory markers